426 related articles for article (PubMed ID: 21883830)
1. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
Lu L; Peters J; Roome C; Stein K
BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
[TBL] [Abstract][Full Text] [Related]
2. A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom.
Lee D; Porter J; Gladwell D; Brereton N; Nielsen SK
J Med Econ; 2014 Apr; 17(4):233-47. PubMed ID: 24568188
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.
Hatoum HT; Crawford ED; Nielsen SK; Lin SJ; Marshall DC
Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):261-70. PubMed ID: 23570437
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
Penson DF; Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M
J Urol; 2005 Aug; 174(2):547-52; discussion 552. PubMed ID: 16006889
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
7. Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Whyte S; Gomersall T; Ren S; Wong R; Chambers D; Tappenden P
Pharmacoeconomics; 2017 Jul; 35(7):717-726. PubMed ID: 27943135
[TBL] [Abstract][Full Text] [Related]
8. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
Bennett CL; Matchar D; McCrory D; McLeod DG; Crawford ED; Hillner BE
Cancer; 1996 May; 77(9):1854-61. PubMed ID: 8646685
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
Bayoumi AM; Brown AD; Garber AM
J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy.
Iannazzo S; Pradelli L; Carsi M; Perachino M
Value Health; 2011 Jan; 14(1):80-9. PubMed ID: 21211489
[TBL] [Abstract][Full Text] [Related]
11. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).
Konski A; Sherman E; Krahn M; Bremner K; Beck JR; Watkins-Bruner D; Pilepich M
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):788-94. PubMed ID: 16109464
[TBL] [Abstract][Full Text] [Related]
12. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
[TBL] [Abstract][Full Text] [Related]
13. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
Kirby RS; Fitzpatrick JM; Clarke N
BJU Int; 2009 Dec; 104(11):1580-4. PubMed ID: 20053189
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
[TBL] [Abstract][Full Text] [Related]
15. [Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer].
Fujikawa K; Awakura Y; Okabe T; Watanabe R; Nishimura S
Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):503-11; discussion 511-2. PubMed ID: 12795165
[TBL] [Abstract][Full Text] [Related]
16. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
Steinberg M
Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
[TBL] [Abstract][Full Text] [Related]
17. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
[TBL] [Abstract][Full Text] [Related]
18. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
Konski A; Watkins-Bruner D; Brereton H; Feigenberg S; Hanks G
Cancer; 2006 Jan; 106(1):51-7. PubMed ID: 16323171
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
20. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]